Declarations
Ethical approval: Ethical approval is not required as this is not a
clinical trial.
Consent: Written informed consent was obtained from the patient for
publication of this case report and the accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of
this journal on request.
Competing interests: The authors
declare there are no conflicting interests.
Funding and sponsorship of this
paper: Self-funding and no sponsorship received.
Author’s contribution: G.K.
analysed the data, designed the paper and wrote the first draft of the
manuscript. J.S. made critical revisions and approved the final
manuscript.
Guarantor: Ganesh Kasinathan is
the guarantor of this manuscript.
Acknowledgements: None
References
- Gupta S, Fenves A, Nance ST, et al. Hyperhemolysis syndrome in a
patient without a hemoglobinopathy, unresponsive to treatment with
eculizumab. Transfusion. 2015; 55(3):623-628
- Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev
Hematol. 2009; 2(2):111-115.
- Win N. Blood transfusion therapy for hemoglobinopathies. In: Practical
Management of Hemoglobinopathies. Okpala 1 (Ed). Blackwell Publishing.
Oxford, UK. 2004; 99-106.
- Segel G, AL Marshall. Direct antiglobulin (Coombs) test-negative
autoimmune hemolytic anemia: A review. Blood cells Mol and Dis. 2014;
52(4):152-60.
- Uhlmann EJ, Shenoy S, Goodnough LT. Successful treatment of recurrent
hyperhemolysis syndrome with immunosuppression and plasma-to-red blood
cell exchange transfusion. Transfusion. 2014; 54(2):384-388.
- Petz LD, Garratty G. Bystander immune hemolysis immune hemolytic
anemias (2nd edition). Churchill Livingstone, PA,
USA. 2004; 358-364.
- Garratty G. Severe reactions associated with transfusion of patients
with sickle cell disease. Transfusion. 1997; 37:357-361.
- Morawakage LR, Perera BJ, Dias PD, et al. Hyperhemolysis in a patient
with beta-thalassemia major. Asian J Transfus Sci. 2009; 3(1):26-27
- Reid ME, Lomas-Francis C. The blood group antigen: facts book. The
blood group system and antigen. San Diego: Academic Press. 2014;
111-112.
- May-Wewres J, Kaiser JR, Moore EK, et al. Severe neonatal analysis due
to maternal antibody to low frequen cy Rh antigen
Cw. Am J Perinatol. 2006; 23:213-217.
- Trial J, rice L. Erythropoietin withdrawal leads to destruction of
young red cells at the endothelial-macrophage interface. Curr.
Pharmaceut. Design. 2004; 10(2):183-190.
- Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of
intravenous immune globulin for hematologic conditions. Transfusion
Med. Rev. 2007; 21:S9-S56.
- Bachmeyer C, Maury J, parrot A, et al. Rituximab as an effective
treatment of hyperhemolysis syndrome in sickle cell anemia. Am J
Hematol. 2010; 85:91-2.
- Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for
delayed hemolysis transfusion reaction in sickle cell disease
patients. Blood. 2016; 127(8):1062-1064.
- Mechery J, Abidogun K, Crosfill F, et al. Hyperhemolysis syndrome
complicating pregnancy in homozygous deltabeta thalassemia.
Hemoglobin. 2012; 36(2):183-185.